Update on regulatory review intervals for ophthalmic new drug applications at the United States Food and Drug Administration.

G. Novack
DOI: https://doi.org/10.1016/S0002-9394(00)00579-1
2000-11-01
Abstract:
What problem does this paper attempt to address?